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Abstract
Objectives
To determine the real world safety of dabigatran or
rivaroxaban compared with warfarin in terms of
gastrointestinal bleeding.
Design
Retrospective cohort study.
Setting
Large administrative database of commercially insured
people in United States from 1 October 2010 through
31 March 2012.
Participants
Enrollees with a prescription of warfarin, dabigatran,
or rivaroxaban between 1 October 2010 and 31 March
2012, who were aged 18 years or older, had continuous
enrollment and no oral anticoagulant use during the
six months before the entry date, with known age and
sex, and with no gastrointestinal bleeding for at least
six months before the cohort entry date. The final study
sample of 46 163 patients included 4907 using
dabigatran, 1649 using rivaroxaban, and 39 607 using
warfarin.
Main outcome measure
Time to gastrointestinal bleeding. Hazard ratios were
derived from Cox proportional hazard models with
propensity score weighting and robust estimates of
errors.
Results
Dabigatran users tended to be older (dabigatran v
rivaroxaban v warfarin: 62.0 v 57.6 v 57.4 years) and
more likely to be male (69% v 49% v 53%). The rate of
gastrointestinal bleeding was highest among
dabigatran users and lowest among rivaroxaban users
(dabigatran v rivaroxaban v warfarin: 9.01 v 3.41 v 7.02
cases per 100 person years). After adjustment for
potentially confounding covariates, there was no
evidence of a statistically significant difference in the
risk of gastrointestinal bleeding between dabigatran
and warfarin users (adjusted hazard ratio 1.21, 95%

What is already known on this topic
Most evidence on the increased risk of gastrointestinal bleeding for novel oral
anticoagulants compared with warfarin comes from clinical trials providing limited
duration of follow-up and selective inclusion criteria
Observational studies have been inconsistent on the association with
gastrointestinal bleeding of dabigatran compared with warfarin

What this study adds
A 50% increase in the risk of gastrointestinal bleeding associated with dabigatran
compared with warfarin cannot be ruled out
A more than twofold increased risk of bleeding with rivaroxaban compared with
warfarin cannot be ruled out
the bmj | BMJ 2015;350:h1585 | doi: 10.1136/bmj.h1585

confidence interval 0.96 to 1.53) or between
rivaroxaban and warfarin users (0.98, 0.36 to 2.69).
Conclusions
Although rates of gastrointestinal bleeding seem to be
similar in this commercially insured sample of adults
in the United States, we cannot rule out as much as a
50% increase in the risk of gastrointestinal bleeding
with dabigatran compared with warfarin or a more than
twofold higher risk of bleeding with rivaroxaban
compared with warfarin.

Introduction
Anticoagulants are widely prescribed in the United
States, the United Kingdom, and around the world for
various conditions including atrial fibrillation.1 Dabigatran and rivaroxaban are available as alternatives to
warfarin for the prevention of stroke in atrial fibrillation.
These drugs offer several advantages over warfarin,
including simplified dosing, fewer drug interactions,
and no requirement for monitoring. As the pharmacokinetic half life of novel anticoagulants is relatively brief,
their pharmacologic effects are transient and disappear
within a week.
Clinical trials have established the relative efficacy or
non-inferiority of these agents compared with warfarin
in selected patients.2 3 For example, in the Randomized
Evaluation of Long-Term Anticoagulant Therapy (RELY) trial,4 dabigatran administered at a dose of 150 mg
was associated with lower rates of stroke and systemic
embolism (1.11% v 1.71%; P<0.001) compared with warfarin. In this trial, both drugs had similar rates of major
hemorrhage (annual major bleeding risk 3.32% v 3.57%
for dabigatran v warfarin; P=0.32). However, the rates of
gastrointestinal bleeding were higher with dabigatran.
The Rivaroxaban versus Warfarin in Nonvalvular Atrial
Fibrillation (ROCKET-AF) trial showed that rivaroxaban
at a 10 mg dose was non-inferior to warfarin for the outcome of stroke and systemic embolism.5 As with the
RE-LY trial, no differences were seen in rates of major
bleeding between warfarin and rivaroxaban in the
ROCKET-AF trial, although rates of fatal bleeding were
lower in the rivaroxaban arm.
Despite the insights that these trials provide, the real
world safety of these novel oral anticoagulants compared with warfarin from limited observational studies
is less clear.6–9 Such safety may diverge from the trial
results for several reasons, including trials’ selective
inclusion criteria as well as the limited duration of these
investigations. Information on findings on gastrointestinal safety will allow clinicians to weigh the risks and
benefits of these agents. Gastrointestinal bleeding carries substantial morbidity and mortality. In the United
States in 2009, an estimated 140 000 or more hospital
admissions had the principal diagnoses of gastrointestinal
1
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bleeding and their aggregate costs reached $1.15bn
(£0.77bn; €1.06bn).10 The incidence of upper gastrointestinal bleeding in the United Kingdom was 103 cases
per 100 000 adults per year.11 Among patients admitted
to hospital with acute upper gastrointestinal bleeding
in the United Kingdom in 2007, the overall mortality
rate was 10%12; among UK patients with atrial fibrillation with warfarin induced gastrointestinal bleeding,
6% of such bleeds are fatal.13
Post-marketing reports have noted reports of major
bleeding associated with dabigatran among older
patients, those at the extremes of body weight, and
those with impaired renal function. Such patients have
been largely excluded from the trials.14 Approximately
25% of the bleeding events in post-marketing reports
were associated with prescribing and dosing error. Concomitant use of antiplatelet drugs with dabigatran
increases the risk of bleeding.15 The proportion of
patients taking antiplatelet drugs is higher in the real
world, making such patients susceptible to bleeding
complications. Furthermore, in contrast to warfarin, no
specific antidote for dabigatran exists and it is not dialyzable.
We did a retrospective cohort study using a large
administrative claims database of commercially insured
people to quantify the comparative safety of these novel
anticoagulants relative to warfarin with respect to
major gastrointestinal bleeding. We focused on gastrointestinal bleeding because of earlier signals in pivotal
clinical trials suggesting an increase in gastrointestinal
bleeding with dabigatran relative to warfarin. Additionally, these novel agents have been approved only
recently and assessing the efficacy of long term outcomes such as stroke without incurring adequate follow-up would be premature.

Methods
Data
We used the IMS Health LifeLink Health Plan Claims
Database. This database contains commercial health
plan information from managed care plans and other
sources (such as Medicare and Medicaid) throughout
the United States, and it is generally representative of
the national, commercially insured population in terms
of age and sex.16 The database contains claims files and
enrollment files. We used the claims files to derive information on inpatient and outpatient diagnoses documented as the ICD-9-CM (international classification of
diseases, ninth revision, clinical modification) codes,
procedures as the Current Procedural Terminology
(CPT-4) codes or the Healthcare Procedural Coding System (HCPCS), prescriptions as National Drug Code
(NDC), date of services, and days of the prescription
supplied. We used the enrollment files to derive information about patients’ demographic characteristics
(including year of birth and sex) and monthly medical/
pharmacy enrollment indicators.
Study population
Our study population included 244 872 enrollees with a
prescription of warfarin, dabigatran, or rivaroxaban
2

between 1 October 2010 and 31 March 2012. We entered
each person into the cohort at the date of his or her first
prescription for any of the three study drugs after 1
October 2010. To be eligible for this study, we required
people to be aged 18 years or older, have continuous
medical and pharmacy enrollment in the six months
before the entry date (the baseline period), have none of
the three drugs prescribed in the baseline period (new
user design), have the first prescription before 31 March
2012, have known age and sex, and not have a previous
bleeding event. The final study sample of 46 163
patients included 4907 dabigatran users, 1649 rivaroxaban users, and 39 607 warfarin users (fig 1).
We defined a patient’s observation ending date as
the earliest of five dates. The first of these was the last
date of (continuous) exposure to the same drug. The
last exposure date was the last day of continuous drug
at hand plus 14 days; we used these 14 days to take into
account the clearance of the drug. For example, if
there was a gap of 14 days or less between two consecutive prescriptions of the same drug, we considered
the exposure to be continuous. However, if a patient
switched to another drug within the 14 day period of
the previous exposure, we considered the day before
the start of the second drug to be the last exposure
date. The second date was the date of the loss of medical or pharmacy enrollment. The third was the end
date of the study, which was 31 March 2012. The fourth
was the date before the first date of hospital admission
not related to gastrointestinal bleeding, because we
did not have prescription information during hospital
admission. The last date was the first date of gastrointestinal bleeding. If gastrointestinal bleeding occurred
during hospital admission, we used the first date of
admission as the bleeding date for patients admitted
for gastrointestinal bleeding. We censored a patient if
the observation ending date was not equal to the first
bleeding date.

Outcome and independent variables
Our independent variable of interest was the type of
drug exposure: warfarin, dabigatran, or rivaroxaban.
We used control variables including demographics (age
groups, sex, and region), three binary clinical conditions (having any diagnosis of renal failure, trauma, or
Helicobacter pylori infection), three binary drug indicators (having any prescription of non-steroidal anti-inflammatory drugs, proton pump inhibitor, or steroid),
and six levels of counts of Clinical Classification Software (CCS). The CCS is a tool, developed by the Agency
for Healthcare Research and Quality, for clustering
patients’ diagnoses and procedures into a manageable
number of clinically meaningful categories17; the higher
the CCS score, the higher the comorbidity. All variables
were derived from claims data in the baseline period.
We incorporated propensity scores into the models as a
means of weighting the observations to account for
potential confounding by the variables above. Our outcome of interest was gastrointestinal bleeding, which
we identified using ICD-9 codes and CPT codes validated in a recent study (web appendix 1).18
doi: 10.1136/bmj.h1585 | BMJ 2015;350:h1585 | the bmj
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Patients excluded:
Age <18 years (n=1057).
Without continuous medical enrollment over 6 months before cohort entry date (n=74 289)
Without continuous drug enrollment over 6 months before cohort entry date (n=87 722)
Not new user (n=119 026).
First prescription of oral anticoagulant after 31 March 2012 (n=7880)
Missing sex information (n=395)
Had previous bleeding (n=12 979; 10 693 in pre-baseline period and 3533 in baseline period)
Eligible patients (n=46 163):
Dabigatran users (n=4907)

Rivaroxaban users (n=1649)

Warfarin users (n=39 607)

Fig 1 | Flow chart of sample size

Propensity score
To control for the differences in patients’ characteristics
across warfarin, dabigatran, and rivaroxaban users, we
developed two propensity scores: one to predict
whether a person used dabigatran relative to warfarin
among dabigatran and warfarin users (n=44 514) and
another to predict use of rivaroxaban relative to warfarin among rivaroxaban and warfarin users (n=41 256).
To develop these propensity scores, we included the
aforementioned control variables; the only exception
was that we entered CCS into the propensity score
model as 285 mutually exclusive binary indicators.
Various methods have been proposed to apply propensity scores, including matching, inverse probability
of treatment weighting, stratification, and regression
covariates; each has its own advantages and disadvantages, and no single method consistently outperforms
other approaches.19–21 We used propensity score weighting because we did not want to lose the observations of
treated patients (compared with matching) and we
wanted one interpretable overall treatment effect (compared with stratification). We applied the average treatment effect of the treated weighting because this allows
us to estimate the average effect of treatment on patients
who received the treatment; that is, we compared the
hazards of gastrointestinal bleeding among dabigatran
or rivaroxaban users with the hypothesized situation
had they taken warfarin instead of the oral anticoagulant. This is particularly useful when the study sample
is likely to differ systematically from the overall population.19 We compared the balance in baseline covariates
before and after weighting by using the standardized
difference; we considered a standardized difference less
than 0.1 to be a negligible difference between treatment
groups.19 After we applied average treatment effect of
the treated weighting, standardized differences of all
available covariates between dabigatran and warfarin
users and between rivaroxaban and warfarin users were
reduced to 0.05 or smaller, suggesting that the groups
were well balanced (appendix 2).
Statistical analysis
We used χ2 tests and analysis of variance/Kruskal-Wallis tests to examine whether patients’ characteristics
were different across the three groups of drug users. We
the bmj | BMJ 2015;350:h1585 | doi: 10.1136/bmj.h1585

present Kaplan-Meier survival curves of having gastrointestinal bleeding stratified by the three different drug
groups (fig 2). We created two separate Cox proportional
hazard models with propensity score average treatment
effect of the treated weighting to examine the association between anticoagulant exposure (“dabigatran v
warfarin” and “rivaroxaban v warfarin”) and gastrointestinal bleeding, and we calculated robust estimates of
standard errors for all variables in the model.22 Control
variables could enter the model as either regression
covariates or stratification factors; if a variable violated
the proportional hazard assumption, this variable
would enter the model as a stratification factor. We
started with all control variables as regression covariates and examined whether the proportional hazard
assumption was violated for any control variable at the
P=0.1 level (Kolmogorov-type supremum test).23 Across
two models, three variables reached that level—age
groups, CCS categories, and having any use of non-steroidal anti-inflammatory drug in the baseline period;
these were later included in the model as stratification
factors. We re-checked the proportional hazard assumption and found that it was not violated with all remaining variables (P≥0.1). We also did a post hoc analysis
stratifying our results for patients above and below the
age of 65 years, using the same model as for the total
sample. We used SAS version 9.2 for all analyses.

Sensitivity analyses
We used several sensitivity analyses to examine
whether our findings were robust. Firstly, we evaluated
two additional models: one including all variables as
regression covariates and another including all variables as stratification factors. Secondly, we varied the
length of washout period from seven to 30 to 45 days to
check the robustness of our results. Thirdly, we censored all inpatient records owing to the lack of the prescription information during hospital admission, as we
wanted to examine whether such exclusion would
affect our findings. Finally, we additionally included
the HAS-BLED (hypertension, abnormal renal/liver
function, stroke, bleeding history or predisposition,
Survival probability

Patients with prescription claim of oral anticoagulants after 1 October 2010 (n=244 872):
Dabigatran users (n=14 089) Rivaroxaban users (n=4450) Warfarin users (n=226 333)
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Fig 2 | Survival function and number of patients at risk over
time by drug use
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labile international normalized ratio, elderly, drugs/
alcohol concomitantly) bleeding risk score in the model
to control for a patient’s risk of bleeding and examine
whether our results would change.24–26 Given that we
did not have laboratory data, we excluded the labile
international normalized ratio from construction of this
risk score.

Results
Among 46 163 patients included in the study, about
85.8% were warfarin users; fewer used dabigatran
(10.6%) or rivaroxaban (3.6%) (table 1). Dabigatran
users were the oldest (dabigatran v rivaroxaban v warfarin: 62.0 v 57.6 v 57.4 years) and most likely to be male
(69% v 49% v 53%). Overall, the CCS score was lower in
dabigatran and rivaroxaban users than in warfarin

Table 1 | Characteristics of study sample. Values are percentages (numbers) unless
stated otherwise
Dabigatran
(n=4907)

Rivaroxaban
(n=1649)

Warfarin
(n=39 607)

Total
(n=46 163)

62.0 (12.0)

57.6 (9.8)

57.4 (13.5)

57.6 (13.3)

18–44

6.0 (295)

8.1 (133)

14.9 (5909)

13.7 (6337)

45–64

16.9 (827)

25.5 (420)

22.6 (8962)

22.1 (10 209)

55–64

44.4 (2178)

49.0 (808)

40.1 (15 867)

40.8 (18 853)

≥65

32.8 (1607)

17.5 (288)

22.4 (8869)

23.3 (10 764)

30.9 (1514)

51.5 (849)

46.9 (18 568)

45.3 (20 931)

East

10.5 (515)

3.9 (65)

11.1 (4391)

10.8 (4971)

Mid-West

29.6 (1450)

33.7 (555)

37.0 (14 648)

36.1 (16 653)

South

49.5 (2431)

55.4 (913)

40.4 (15 982)

41.9 (19 326)

West

10.4 (511)

7.0 (116)

11.6 (4586)

11.3 (5213)
4.9 (2245)

Patients’ characteristics
Mean (SD) age, years
Age group*:

Female sex*
Region*:

Clinical/medication indicators from baseline period
Renal failure*

4.2 (207)

2.1 (34)

5.1 (2004)

Trauma*

13.3 (653)

27.7 (457)

23.3 (9240)

22.4 (10 350)

Helicobacter pylori infection 0.2 (11)

0.2 (3)

0.1 (54)

0.2 (68)

Mean (SD) CCS score

12.3 (5.6)

13.5 (8.5)

13.2 (8.2)

11.3 (6.9)

CCS category*:
≤5

18.60 (912)

8.3 (136)

14.9 (5917)

15.1 (6965)

6–10

33.5 (1642)

30.2 (498)

25.6 (10 147)

26.6 (12 287)

11–15

25.5 (1253)

37.1 (612)

25.8 (10 218)

26.2 (12 083)

16–20

13.0 (640)

16.3 (268)

16.5 (6532)

16.1 (7440)

21–25

5.2 (254)

6.3 (103)

8.4 (3332)

8.0 (3689)

≥26

4.2 (206)

1.9 (32)

8.7 (3461)

8.0 (3699)

NSAID use*

15.6 (764)

43.7 (721)

23.9 (9475)

23.7 (10 960)

PPI use

18.7 (916)

19.2 (316)

19.5 (7734)

19.4 (8966)

Steroid use*

12.5 (615)

12.7 (209)

15.3 (6074)

14.9 (6898)

No with gastrointestinal
bleeding*

122

4

632

758

Total person years
Rate of gastrointestinal
bleeding (per 100 person
years)
Median (IQR) observation
time, days*

1354.0
9.01

117.4
3.41

9007.1
7.02

10 478.5
7.23

70 (45–133)

25 (18–30)

47 (35–105)

45 (33–105)

Outcome

Source: IMS Health LifeLink® Health Plan Claims Database, 2010–12.
CCS=Clinical Classification Software; NSAID=non-steroidal anti-inflammatory drug; PPI=proton pump inhibitor.
*P≤0.01.
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users (dabigatran v rivaroxaban v warfarin: 11.3 v 12.3 v
13.5). The number of cases of gastrointestinal bleeding
among dabigatran users was 122 compared with only
four among rivaroxaban users. The rate of gastrointestinal bleeding was highest among dabigatran users and
lowest among rivaroxaban users (dabigatran v rivaroxaban v warfarin: 9.01 v 3.41 v 7.02 per 100 person years).
Table 2 shows the unadjusted and adjusted results of
the average treatment effect of the treated for the total
sample and for patients under and over 65 years of age.
Appendix 3 shows the results of the full model for the
total sample.
Without adjusting for any covariate, we found no
statistically significant difference between dabigatran
and warfarin in the risk of gastrointestinal bleeding;
the crude hazard ratio was 1.20 (95% confidence interval 0.96 to 1.52). After adjustment for age groups, CCS
categories, and non-steroidal anti-inflammatory drug
use as stratification factors and for sex, regions, three
binary clinical conditions (having any diagnosis of
renal failure, trauma, or Helicobacter pylori infection),
and two binary medication indicators (having any prescription of proton pump inhibitor or steroid) as
regression covariates, the adjusted hazard ratio was
1.21 (0. 96 to 1.53).
Without adjusting for any covariate, we found no statistically significant difference between rivaroxaban
and warfarin in the risk of gastrointestinal bleeding; the
crude hazard ratio was 0.95 (0.31 to 2.94). After adjustment for age groups, CCS categories, and non-steroidal
anti-inflammatory drug use as stratification factors and
all other confounders as regression covariates, the
adjusted hazard ratio was 0.98 (0.36 to 2.69).
Appendix 4 shows the sensitivity analyses with different covariate inclusion methods, and appendix 5
shows those with three different washout periods for
warfarin users. Appendix 6 shows the results with censoring of inpatient gastrointestinal bleeding, and
appendix 7 shows those including HAS-BLED risk score.
Results from these sensitivity analyses were very similar, suggesting that our findings were robust.
We found no statistically significant differences (at
the P=0.05 level) in the adjusted hazard ratios comparing dabigatran or rivaroxaban users with warfarin users
among patients under or over the age of 65. However,
when we compared dabigatran and warfarin users
under 65, the adjusted hazard ratio was borderline
significant (P<0.1) (adjusted hazard ratio 1.33, 0.98 to
1.83), suggesting a potentially increased risk associated
with dabigatran.

Discussion
In this analysis of novel oral anticoagulant use among
commercially insured people in the United States, neither dabigatran nor rivaroxaban was associated with a
statistically significantly increased risk of gastrointestinal bleeding relative to warfarin. These findings are
important given the global burden of thromboembolic
disease, as well as the recent development of several
novel oral anticoagulants of which the real world safety
and effectiveness relative to warfarin remain unclear.
doi: 10.1136/bmj.h1585 | BMJ 2015;350:h1585 | the bmj
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Table 2 | Multivariable association between novel oral anticoagulant use and
gastrointestinal bleeding
Analysis

Dabigatran (reference
group: warfarin)

Rivaroxaban (reference group:
warfarin)

All patients:
Crude hazard ratio* (95% CI)
Adjusted hazard ratio† (95% CI)
Patients aged under 65 years:
Crude hazard ratio* (95% CI)
Adjusted hazard ratio† (95% CI)
Patients aged over 65 years:
Crude hazard ratio* (95% CI)
Adjusted hazard ratio† (95% CI)

(n=44 514)
1.20 (0.96 to 1.52)
1.21 (0.96 to 1.53)
(n=34 038)
1.33 (0.98 to 1.80)
1.34 (0.98 to 1.83)
(n=10 476)
1.07 (0.75 to 1.52)
1.07 (0.75 to 1.53)

(n=41 256)
0.95 (0.31 to 2.94)
0.98 (0.36 to 2.69)
(n=32 099)
1.08 (0.27 to 4.41)
1.03 (0.33 to 3.18)
(n=9157)
0.69 (0.10 to 4.68)
0.62 (0.18 to 2.08)

Source: IMS Health LifeLink® Health Plan Claims Database, 2010–12.
*No control variables.
†Age groups, Clinical Classification Software categories, and non-steroidal anti-inflammatory drug use as
stratification factors and others as regression covariates.

Comparison with previous studies
Our inability to detect a statistically significant difference
in gastrointestinal bleeding between dabigatran and
warfarin is noteworthy, given that several studies examining this outcome have identified such an association.
For example, a meta-analysis of clinical trials reported a
statistically significant increased risk of gastrointestinal
bleeding with novel anticoagulants, with a relative risk of
1.45 (95% confidence interval 1.07 to 1.97). The odds ratio
for dabigatran was 1.58 (1.29 to 1.93), and that for rivaroxaban was 1.48 (1.21 to 1.82).27 A recent study focusing on
older US Medicare patients with non-valvular atrial fibrillation reported an increase in gastrointestinal bleeding
with dabigatran compared with warfarin (hazard ratio
1.28, 1.14 to 1.44).28 These differences may be due to differences in the study populations; our study participants
were relatively younger compared with the Medicare
cohort. The excess hazard of dabigatran, relative to warfarin, may be age dependent and concentrated among
very elderly people, a population that was not well represented in this sample of commercially insured patients.
In contrast, our analysis showed that the risk of bleeding
with dabigatran relative to warfarin was higher among
patients under 65, although this was not significant
(adjusted hazard ratio 1.33, 0.98 to 1.80). Major gastrointestinal bleeding events were statistically significantly
higher with the 150 mg dose of dabigatran compared
with warfarin in the RE-LY trial (relative risk 1.30, 1.08 to
1.56).29 However, the population was older than that in
our study. Another small hospital based study reported
no difference in the risk of gastrointestinal bleeding
among dabigatran compared with rivaroxaban users
(5.3% v 4.8%; P=0.82).9 Another database study reported
no difference in the rates of gastrointestinal bleeding
between rivaroxaban and warfarin users among patients
with non-valvular atrial fibrillation.6
Other observational studies have similarly reported
either very low rates of gastrointestinal bleeding or no
difference in rates between warfarin and dabigatran in
several European cohorts.7 8 However, these studies
had several drawbacks including limited efforts in
ensuring baseline balance across different exposure
groups (propensity score matching based on up to
the bmj | BMJ 2015;350:h1585 | doi: 10.1136/bmj.h1585

three simple variables, or none26); not adopting a new
user design so that previous exposure might affect the
observed outcomes; focusing on prevalent instead of
incident outcomes; basing the classification of exposure group on the first eligible claims; and not requiring continuous exposure. The different results
observed from clinical trials and observational studies
likely reflect differences in populations enrolled in
these studies and the selection of participants to
receive these drugs. It is important to note here that
several of these European cohort studies reporting no
difference in bleeding included the lower 110 mg dose
of dabigatran, which is widely used in other countries.
The US Food and Drug Administration has not allowed
the use of 110 mg dabigatran in the United States, so
our study did not include such users. A recent analysis
of documents suggested that the plasma concentrations of the drug vary substantially across users. This
variability in blood concentrations could also be associated with differences in rates of adverse effects such
as gastrointestinal bleeding.30 31
Our results showing no evidence of a difference in the
risk of gastrointestinal bleeding with rivaroxaban
compared with warfarin are similar to a recent observational from the United Stated that reported no statistically significant difference in real world rates of
bleeding between rivaroxaban and warfarin in patients
with non-valvular atrial fibrillation (hazard ratio 1.06,
0.71 to 1.64).6

Strengths and weaknesses of study
Our study has several strengths. Firstly, we adopted a
new user design, which allowed us to eliminate the
residual effect of the previous exposure. Secondly, we
focused on the incident cases to remove the effect of
prevalent gastrointestinal bleeding, an important risk
factor for subsequent bleeding. Thirdly, we used a validated algorithm to identify gastrointestinal bleeding
cases. Fourthly, we included a wide range of potential
confounders identified from the literature in constructing propensity scores. Fifthly, baseline balance between
different exposure groups was achieved through the
propensity score weighting and evaluated through the
standardized difference to minimize confounding.
Sixthly, we did several sensitivity analyses to evaluate
the robustness of our results, including varying length
of exposure washout periods and different methods of
applying propensity scores.
Our study also has some limitations. Firstly, we did
not have access to information about patients’ mortality
or about laboratory tests such as prothrombin times.
Secondly, we assumed that prescription fill data reflect
actual patient usage. Thirdly, our inability to detect a
significant difference between dabigatran and warfarin
may have been a result of a low number of events resulting in inadequate statistical power. Fourthly, our outcome of interest, gastrointestinal bleeding, may not
have been fully captured by the algorithm. However, we
used an approach that has been validated with reasonable accuracy in a previous study.18 Fifthly, this study
might underestimate bleeding associated with novel
5
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agents, as patients are more likely to report and seek
treatment for bleeding associated with these agents
than for warfarin. Sixthly, the short observation time
might not allow us to explore other important long term
bleeding effects. In addition, the length of observation
was different across the three drug user groups, with
the shortest observation period for rivaroxaban users.
Seventhly, we have limited clinical information on
patients excluded from the cohort. The generalizability
of these findings to European cohorts and those taking
lower doses of dabigatran 110 mg is unknown. Eighthly,
the average treatment effect of the treated weighting
results in effect estimates standardized to different populations (rivaroxaban users or dabigatran users). Given
the substantial differences between the two groups, the
effect estimates could not be directly compared. Finally,
our findings may be subject to unmeasured confounding. For example, it is particularly difficult to capture
aspirin, which is obtained over the counter and a significant risk factor for gastrointestinal bleeding. Selection
bias whereby health professionals may have channeled
patients at risk of gastrointestinal bleeding to one class
of agents is always possible.

Priorities for future research
Our findings raise questions and opportunities for further investigation. For example, future studies should
consider other designs, such as the self controlled case
series, to control for time invariant, within person confounding.32 Such studies should also evaluate additional outcomes such as overall bleeding and benefits
such as reduction in thromboembolic stroke. Another
novel anticoagulant—apixaban—is now available and
should also be evaluated as a comparator in future
studies. In addition, given evidence suggesting variations in the risk of gastrointestinal hemorrhage with
age, studies with adequate samples of older people are
important to evaluate this association further. Finally,
most of our study patients exited the cohort owing to
loss of continuous drug exposure (46% for dabigatran
users, and about 60% for rivaroxaban and warfarin
users; see appendix 8). Many factors may contribute to
this phenomenon, including the short length of washout period (for example, if the length was expanded to
45 days, the proportion would reduce to 27% for dabigatran users and about 40% for others), patients’ unwillingness to fill the prescription (due to side effects, costs,
or other concerns), or information not recorded on
claims data (patients might have obtained the drug but
it was not recorded on claims—for example, by obtaining samples or paying cash). In a Chinese atrial fibrillation patient cohort prescribed dabigatran (n=467), 22%
permanently discontinued dabigatran; the most common reason for discontinuation was dyspepsia (31%),
followed by other adverse events (18%), such as minor
bleeding (9%), major gastrointestinal bleeding (8%),
and intracranial hemorrhage (1%); cost concerns
accounted for 1%.33 Better understanding of the reasons
behind discontinuation may help to increase patients’
adherence rates and help patients to increase the quality
of medical care they receive.
6

Implications and conclusions
Our findings have clinical and policy implications. In
the light of other studies that suggest an increased risk
of gastrointestinal bleeding associated with dabigatran,
our findings show a null effect in a relatively younger
insured population. However, these findings are not
inconsistent with previous studies and do not rule out a
greater than 50% increased risk with dabigatran and
more than twofold increased risk with rivaroxaban.
Pharmacy benefit managers, insurers, and guideline
makers may also use this information to make evidence
based decisions about the group of patients who are eligible for therapy.
In this commercially insured database of adults in
the United States, neither dabigatran nor rivaroxaban
use was associated with a statistically significantly
increased risk of gastrointestinal bleeding relative to
warfarin. Evidence from observational studies such
as ours should prove useful to clinicians in selecting
the appropriate anticoagulant for patients after incorporating other information about the safety, efficacy,
and effectiveness of these agents, as well as their
cost and patients’ preferences regarding anticoagulant therapy.
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